Intravenous Infusions Plc (GHSE:IIL)

Intravenous Infusions Revenue

Intravenous Infusions had revenue of 2.23M GHS in the half year ending December 31, 2025, a decrease of -87.50%. This brings the company's revenue in the last twelve months to 6.51M, down -66.42% year-over-year. In the year 2025, Intravenous Infusions had annual revenue of 9.30M, down -62.69%.

• Revenue (ttm): 6.51M
• Revenue Growth: -66.42%
• P/S Ratio: 32.86
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 214.04M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	9.30M	-15.64M	-62.69%
Dec 31, 2024	24.94M	-6.48M	-20.62%
Dec 31, 2023	31.42M	11.06M	54.34%
Dec 31, 2022	20.36M	-2.32M	-10.21%
Dec 31, 2021	22.67M	2.00M	9.69%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 3, 2026

Data Sources Report a data error